Saturday, July 12, 2025

Latest

Revive Therapeutics Closes $23.0 Million Bought Deal Financing

Revive Therapeutics (CSE: RVV) this morning announced the closing of its bought deal financing. Originally announced at a figure of $10.0 million, strong demand lead to it being doubled to $20.0 million, before closing out today at $23.0 million with the exercise of the over-allotment option.

The financing saw units of the company sold at a price of $0.50 per each, with each unit containing one common share and one common share purchase warrant. Each warrant is valid for a period of three years and contains an exercise price of $0.70 per share.

An acceleration clause is also present on the warrant, enabling the company to accelerate the expiry date in the event that the equity trades above $1.10 for ten consecutive days on a volume weighted basis.

Net proceeds from the offering are to be used for phase 3 clinical costs for its study on the use of Bucillamine in the treatment of mild to moderate COVID-19, phase 1 clinical costs for the firms psilocybin for methamphetamine use disorder study, and other psychedelic formulation development work, as well as working capital and general corporate purposes.

Revive Therapeutics last traded at $0.65 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Mergers Set the Stage for Uranium’s Growth Cycle | Forum-Baselode Merger

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Recommended

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

Related News

Revive Receives Approval From Independent Review Board For Phase Three Study

Revive Therapeutics (CSE: RVV) is one step closure to commencing its phase three clinical trials...

Monday, August 31, 2020, 08:56:26 AM

Revive Therapeutics Selects Novotech As APAC Contract Research Organization

Revive Therapeutics (CSE: RVV) this morning has continued its push towards studying Bucillamine as a...

Wednesday, April 8, 2020, 09:37:45 AM

Revive Files Pre-IND Meeting With FDA For COVID-19 Treatment

Revive Therapeutics (CSE: RVV) this morning announced that it has filed its pre-investigational new drug...

Friday, April 3, 2020, 10:44:10 AM

Revive Therapeutics Advances Psilocybin-Based Product Research

Revive Therapeutics (CSE: RVV) this morning announced that it has partnered with Complete Phytochemical Solutions...

Friday, April 17, 2020, 08:38:51 AM

Revive Therapeutics Continues With Phase 3 Clinical Trial For Bucillamine, To File For Emergency Use Authorization

Revive Therapeutics (CSE: RVV) issued an update to the market this morning related to its...

Wednesday, December 23, 2020, 09:48:31 AM